Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis-Reference-Cited by-同舟云学术

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

Published:2022-02-10 Issue:5 Volume:44 Page:1237-1245
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Takenaka Yukinori¹^ORCID,Oya Ryohei¹,Takemoto Norihiko¹,Inohara Hidenori¹

Affiliation:

1. Department of Otorhinolaryngology – Head and Neck Surgery Osaka University Graduate School of Medicine Osaka Japan

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26997

Reference48 articles.

1. National comprehensive cancer network.Clinical practice guidelines in oncology: Head and Neck Cancers.https://www.nccn.org/guidelines/guidelines‐detail?category=1&id=1437. Accessed November 14 2021.

2. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

4. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

5. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors;Acta Oto-Laryngologica;2024-08-10

2. Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent;Cancer Immunology, Immunotherapy;2024-08-02

3. High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse;PLOS ONE;2024-08-01

4. Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Oncology;2024-07-26

5. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma;Current Oncology;2024-07-26